H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Y-Mabs Therapeutics Inc (YMAB) today and set a price target of $40. The company’s shares closed last Monday at $26.16.
Selvaraju noted:
“We have assessed Y-mAbs using a discounted cash flow (DCF)-based methodology, which yields a total enterprise value of $1.46B. We utilize a 90% probability of approval for naxitamab in r/r neuroblastoma and for omburtamab in CNS/leptomenigeal mets from neuroblastoma.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -10.8% and a 26.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Y-Mabs Therapeutics Inc with a $40 average price target, representing a 57.9% upside. In a report released today, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31 and a one-year low of $15.17. Currently, Y-Mabs Therapeutics Inc has an average volume of 165.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
